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Bone production, maintenance, and modeling are a well-balanced process involving
mineralization by osteoblasts and resorption by osteoclasts. Sex steroid hormones,
including their conjugated forms, contribute majorly to maintaining this balance. Recently,
variants in the SLC22A9 gene have been associated with osteoporosis in Korean
females. We had recently shown that SLC22A9, encoding organic anion transporter 7
(OAT7), is an uptake transporter of estrone sulfate and identified several genetic variants
in Europeans leading to functional consequences in vitro. We therefore hypothesized
that SLC22A9 genetic variants may contribute to the pathophysiology of osteoporosis
in Europeans. To test this hypothesis, we examined the associations of SLC22A9
variants with bone quality, fractures, and bone turnover markers. We genotyped
SLC22A9 variants in 5,701 (2,930 female) subjects (age range, 20–93 years) extracted
from the population-based Study of Health in Pomerania (SHIP and SHIP-TREND)
covered by the Illumina Infinium HumanExome BeadChip version v1.0 (Exome Chip).
Descriptive data (e.g., history of fractures), ultrasonography of the calcaneus, as well as
serum concentrations of carboxy-terminal telopeptide of type I collagen, amino-terminal
propeptide of type I procollagen, and vitamin D were determined. Comprehensive
statistical analyses revealed no association between low-frequency and rare SLC22A9
variants and bone quality, fractures, and bone turnover markers. Our results indicate
that single genetic SLC22A9 variants do not have a major impact on osteoporosis risk
prediction in Europeans, yet findings need to be replicated in larger-scale studies.
Keywords: estrone sulfate transporter, SLC22A9, osteoporosis, human association studies, sex steroids
INTRODUCTION
Formation and maintenance of bone is a well-balanced process involving osteoclast-mediated
bone resorption, osteoblast-mediated bone formation, and remineralization. The peak bone mass
is reached around the age of 30; thereafter, bone mass is continuously decreasing because
resorption outweighs formation (1). The complex pathophysiology of bone loss is caused by
a number of genetic, biochemical, hormonal, and environmental factors (1). In particular,
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estrogens and their conjugates contribute majorly to maintaining
the balance between bone formation and resorption. Accelerated
bone loss and compromised bone strength in the elderly increase
the risk for osteoporosis affecting hundreds of million people
worldwide with major clinical consequences such as fractures,
disabilities, and mortality (1–3). It is therefore important to
discover markers for the identification of individuals at risk for
developing osteoporosis.
In addition to serum biomarkers, multiple genetic variants
have been associated with low bone mineral density or increased
fracture risk (2, 4–7). Recently, a missense variant in the SLC22A9
gene was identified in Korean females with osteoporosis but not
in control subjects (8). This missense variant (c.T1277C, p.F426S)
appears to be unique in Koreans because it has not been found
in any population of the public reference exome data sets of the
1000 Genomes Project (9), the Exome Sequencing Project (10),
and the Genome Aggregation Database (11) covering in total
the genetic variation of more than 141,000 unrelated individuals.
SLC22A9 encodes organic anion transporter 7 (OAT7), which is
localized in the hepatocyte basolateral membrane and transports
estrone sulfate (12, 13), the major circulating estrogen metabolite
considered an important precursor of active estrogen (14).
Variants altering transport function, as is the case, e.g., for
missense variant c.T1277C (8), may therefore impact on estrone
sulfate serum levels and eventually on bone formation. The
observation by Ahn et al. (8) has caught our interest because
we had systematically characterized OAT7 and identified three
genetic variants in Europeans (rs377211288, rs61742518, and
rs146027075) leading to functional consequences of estrone
sulfate transport in in vitro cell systems (13). We therefore
hypothesized that genetic variants in SLC22A9 may be novel
biomarkers not only in Koreans but also in Europeans to identify
patients at risk for developing osteoporosis. Our aim was to
assess the association of SLC22A9 genetic variants with bone
quality, fracture risk and serum bone turnovermarkers in a cross-
sectional population-based cohort study from Germany (SHIP)
(15), which had been previously used to identify fracture risk and
risk factors for osteoporosis (16).
MATERIALS AND METHODS
Study Population
The study population is based on data from two independent
population-based cohorts as described in detail previously: the
Study of Health in Pomerania (SHIP) and SHIP-TREND (15, 16).
The baseline investigation in SHIP (SHIP-0) took place between
1997 and 2001. The first follow-up (SHIP-1) was conducted 5
years after baseline between 2002 and 2006. The 11-year follow-
up investigation (SHIP-2) took place at the same time as SHIP-
TREND in 2008–2012. For the present study, we used data from
SHIP-1 (N = 3,300, 25–88 years), SHIP-2 (N = 2,333, 30–93
years), and SHIP-TREND (N = 4,420, 20–84 years). All SHIP
and SHIP-TREND participants have German citizenship, and the
entire sample is Caucasian.
The analyses regarding bone quality and fracture risk were
restricted to SHIP-2 and SHIP-TREND (N = 6,753), as neither
quantitative ultrasound (QUS) measurements at the heel nor
TABLE 1 | Baseline characteristics of the study population.
Characteristic Male (N = 2,771) Female (N = 2,930)
Age (years) 49.9 (15.0) 48.1 (14.5)
BMI (kg/m²) 28.6 (4.4) 27.5 (5.5)
Premenopausal (%) – 1,205 (41.1)
- Intake of oral contraceptives
(%)
– 28.9%
Postmenopausal (%) 1,725 (58.9)
- Intake of menopausal hormone
replacement therapy (%)
– 6.55%
- Self-reported postmenopausal
osteoporosis (%)
9.77%g
Fractures (self-reported) (%) 192 (6.9) 223 (7.6)
BUA (dB/MHz) 117.3 (13.8) 109.3 (14.8)
SOS (m/s) 1,564.3 (37.7) 1,562.2 (33.5)
Bone stiffness index 96.6 (18.2) 90.7 (17.6)
High risk for osteoporotic
fractures (%)
128 (4.6) 198 (6.8)
PINP (ng/ml) 45.2 (19.0)a 46.9 (21.4)b
β-CTX (ng/ml) 0.31 (0.18)c 0.30 (0.20)d
Vitamin D (ng/ml) 24.0 (9.1)e 23.8 (9.8)f
Values are means (SD) or n (%).
BMI, body mass index; BUA, broadband ultrasound attenuation; β-CTX, carboxy-terminal
telopeptide of type I collagen; PINP, amino-terminal propeptide of type I procollagen; SOS,
speed of sound.
aN = 2,711, bN = 2,571, cN = 2,693, dN = 2,825, eN = 1,785, fN = 1,823;
gN = 1,668 postmenopausal women responded to the question regarding a diagnosis
of osteoporosis.
details on fracture history were recorded in the other study waves.
Among these subjects, 6,067 participants had valid QUS data and
were thus eligible for the present study. Subjects with missing
data on self-reported fractures, body mass index, or genotyping
were excluded. Moreover, we excluded all those who reported
intake of antiresorptive drugs used in osteoporosis therapy
(bisphosphonates and selective estrogen receptor modulators) as
well as glucocorticoids for systemic use, which are well-known
causes for secondary osteoporosis. Thus, the study population
for the analysis of bone quality and history of fractures included
5,701 participants.
The analyses regarding the bone turnover markers were
restricted to SHIP-1 and SHIP-TREND (N = 7,720), as
both markers were available only in these cohorts. Again,
taking into account valid QUS, bone turnover and confounder
measurements, as well as medication intake yielded a population
of 5,282 subjects for PINP and 5,518 subjects for the respective
β-CTX analysis.
Finally, the analyses regarding vitamin D were restricted to
the SHIP-TREND cohort (N = 4,420). Among these participants,
3,608 had valid QUS, vitamin D, and confounder data, were not
taking the above defined medication, and were included in the
respective analysis.
Characteristics of the study population are summarized in
Table 1. This observational study conformed to strengthening
the reporting of observational studies in epidemiology (STROBE)
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guidelines for observational studies (17). The study followed
the recommendations of the Declaration of Helsinki (SHIP-0:
version of 1996; SHIP-1, SHIP-2, and SHIP-TREND: version of
2000). The study protocol was approved by the medical ethics
committee of the University of Greifswald, and written informed
consent was obtained from each study participant.
QUS Measurements
Bone quality was assessed by QUS measurements at the heel.
QUS measurements provide information on bone strength and
microarchitecture (18) and allow to identify subjects with a high
osteoporotic fracture risk (19, 20). The QUS measurements in
our study were performed successively on both feet of seated
participants by trained and certified examiners using the Achilles
InSight device (GE Medical Systems Ultrasound) as described
(16). The system measures the speed of sound (SOS) and
the broadband ultrasound attenuation (BUA). From these two
variables, the stiffness index (SI) was calculated, which is a better
indicator for bone quality than its two components alone (21).
The individual stiffness index results are compared automatically
to values obtained in a normal young reference population
(provided with the Achilles InSight). Indices <-2.5 SD indicate
a high osteoporotic fracture risk, indices >-2.5 SD and <-1 SD
denote a medium osteoporotic fracture risk, and indices >-1 SD
indicate a low osteoporotic fracture risk. Data of the foot with the
lower stiffness index was used for statistical analyses. Distribution
of the stiffness index in pre- and post-menopausal women is
shown in Supplementary Figure 1A.
Fractures
Fractures were self-reported in computer-aided personal
interviews. All SHIP-2 and SHIP-TREND participants were
asked if they ever had a fracture without a prior accident.
Moreover, SHIP-2 participants were asked if they had a fracture
after an accident since the baseline examination, while SHIP-
TREND participants were asked if they ever had a proximal
humerus, hip, femoral, or vertebral fracture after an accident.
If any of the questions was answered affirmatively, a positive
fracture history was determined.
Laboratory Measurements
Blood samples were taken from the cubital vein of participants
in the supine position. In SHIP-0 and SHIP-1, blood samples
were obtained between 8.00 a.m. and 8.00 p.m. from non-fasting
participants. In SHIP-2 and SHIP-TREND, blood samples were
obtained between 7.00 a.m. and 2.00 p.m. (92.5% of samples
between 7.00 and 11.00 a.m.). In SHIP-2, the majority of study
participants was non-fasting (92.9%), while in SHIP-TREND,
the majority (61.2%) of participants was fasting for at least 8 h.
Serum aliquots were stored at −80◦C in the Integrated Research
Biobank (Liconic, Lichtenstein) of the University Medicine
Greifswald and used in accordance with its regulations. Serum
intact amino-terminal propeptide of type I procollagen (PINP)
and β isomerized carboxy-terminal telopeptides of type I collagen
(β-CTX) concentrations, also known as β-CTX concentrations,
were determined on the IDS-iSYS Multi-Discipline Automated
Analyzer (Immunodiagnostic Systems Limited, Frankfurt am
Main, Germany) as described (22). The coefficients of variation
for PINP and β-CTX were 7.3 and 12.2% at low concentrations,
5.7 and 10.4% at medium concentrations, and 7.9 and 11.4%
at high concentrations of control material in SHIP-1, as well as
4.4 and 7.5% at low concentrations, 4.5 and 5.2% at medium
concentrations, and 4.3 and 4.5% at high concentrations of
control material in SHIP-TREND. Distribution of the β-CTX
concentrations stratified for pre- and post-menopausal women is
shown in Supplementary Figure 1B. Serum 25-hydroxy vitamin
D was also determined on the IDS-iSYS Multi-Discipline
Automated Analyzer as described (23). The coefficients of
variation for vitamin D were 17.2% at low concentrations, 9.5%
at medium concentrations, and 8.5% at high concentrations of
control material in SHIP-TREND.
Genotypes
SHIP and SHIP-TREND samples were genotyped using the
Illumina Infinium HumanExome BeadChip version v1.0
(Exome Chip). Genomic DNA was hybridized according to the
manufacturer’s standard recommendations at the Helmholtz
Zentrum München. Genotypes were determined using the
Genotyping Module v1.9.4 from the GenomeStudio 2011.11
software with the HumanExome-12-v1-0-B manifest file and
the CHARGE_ExomeChip_v1.0 cluster file. Standard quality
control steps were carried out using PLINK v1.90 (24, 25).
Contaminated samples and samples with a call rate of <90%,
extreme heterozygosity, extensive estimated identical-by-descent
sharing with a large number of samples, or gender mismatch
were excluded. Population outliers were identified by principal
component analysis with smartpca version 10210 using the
Exome Chip ancestry information marker. The final dataset
included 8,219 individuals (3,949 SHIP and 4,270 SHIP-TREND)
with an average call rate of 99.98%. In addition, rs377211288
was genotyped using KASPTM technology (LGC Genomics Ltd.,
Hoddesdon, UK) since this variant was not covered by the
Exome Chip. Primer sequences were as follows: forward primer
allele_X: ATGAGGCCAGAGAAGTGTCGTC, forward primer
allele_Y: CATGAGGCCAGAGAAGTGTCGTT, common
reverse primer: GAGCTGCCACTGAGGATGAACAAA.
Statistical Analysis
Analyses on European ancestry were performed by using the
software packages PLINK v1.90 and R (version 3.4.0 2017-04-21)
(24, 25). Hardy–Weinberg equilibrium calculations were used to
compare observed and expected allele and genotype frequencies
within the study population. Single-variant association analyses
on all variants were performed in PLINK v1.90 considering three
genetic models: additive (homozygote allele 1 vs. heterozygote
vs. homozygote allele 2), dominant (homozygote allele 1 vs.
heterozygote+ homozygote allele 2), and recessive (homozygote
allele 1 + heterozygote vs. homozygote allele 2). Multiple linear
regression analysis was performed for the traits bone quality,
vitamin D, β-CTX, and PINP and multiple logistic regression
analysis for fractures. Models were adjusted for age at blood
taking, sex, BMI, study cohort (except for vitamin D), and
the first 10 principal components to correct for population
stratification. In case of the sex-stratified analyses for women,
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TABLE 2 | Minor allele frequencies (MAF) and other annotations of the SLC22A9 genetic variants assessed by the Illumina ExomeChip array or KASPTM sequencing in the
SHIP and SHIP-TREND study cohort in comparison to the data for non-Finnish Europeans from the Genome Aggregation Database (gnomAD).
refSNP_ID Exome_ID db SNP
alleles
Contig
positiona
Minor
allele
Amino acid
change
MAF (%)
This study
MAF (%)
gnomADb
rs139996395 exm920540 A/G 63137767 G p.Asp80Gly Excludedc 0.0566
rs377211288d C/T 63137796 T p.Arg90Cys 0.0451 0.0116
rs200727459 exm920544 G/A 63137797 A p.Arg90His 0 0.0116
rs138297035 exm920554 G/A 63138694 A p.Gly164Ser 0.0088 0.0031
rs202164269 exm920556 C/G 63141131 G p.Phe174Leu 0.0877 0.0741
rs180967669 exm1726437 G/C 63141180 C p.Ala191Pro 0 7.8e-4
rs139591412 exm920572 C/T 63141435 T p.Ala244Val 0.0088 0.0156
rs79899382 exm920573 A/T 63141443 T p.Thr247Ser 0 0
rs3737458 exm920575 G/A 63141471 A p.Arg256Gln 0.0088 0.0381
rs201479912 exm920579 G/A 63143137 A p.Arg284Gln 0 0.0026
rs200498139 exm920580 C/A 63143153 A p.Gln289Lys 0.0088 0.0163
rs1801401 exm920582 C/A 63143227 A p.Thr314Asn 0 0.0062
rs201804022 exm920585 C/A 63149670 A p.Gln332Lys 0 0.0236
rs141060614 exm920591 C/T 63149746 T p.Thr357Met 0.0088 0.0048
rs182247457 exm920593 A/G 63173982 G p.Met363Val 0.0702 0.0853
rs138875094 exm920594 T/G 63174033 G p.Phe380Val 0 0.0023
rs78019460 exm920597 T/C 63174102 C p.Tyr403His 0 0
rs61742518 exm920601 C/T 63175593 T p.Thr433Met 2.6837 2.979
rs144303933 exm920603 G/A 63175599 A p.Arg435His 0.0088 0.0506
rs139254772 exm920609 T/A 63175663 A p.His456Gln 0.0263 0.0148
rs147323107 exm920610 C/A 63175679 A p.Pro462Thr 0 0.0016
rs146027075 exm920613 A/G 63176187 G p.Ile479Met 0.9560 0.8855
rs149660130 exm920619 T/G 63176294 G p.Leu515Arg 0.0175 0.0155
rs142543443 exm920628 C/T 63177324 T p.Thr551Met 0.0088 0.0124
aContig position refers to chromosome 11, GRCh37 build.
bValues from gnomAD v2.1.1 for non-Finnish Europeans (https://gnomad.broadinstitute.org) (11).
cVariant excluded due to insufficient call rate.
dVariant sequenced by KASPTM technology since it was not included on the ExomeChip.
models were additionally adjusted for menopause (except for
vitamin D). Traits for PINP and β-CTX were log-transformed
and winsorized by 5 standard deviations from themean to reduce
the impact of outliers. For vitamin D, a rank-based inverse
normal transformation was performed. Bonferroni correction
was used to adjust P-values for multiple testing. A P < 0.05 was
considered significant.
RESULTS
SLC22A9 Genetic Variants and Allele
Frequencies
A total of 24 missense variants in the SLC22A9 gene were
analyzed (Table 2). Twenty-three variants were assessed using
the Exome Chip, and from these, variant exm920540 was
excluded due to an insufficient call rate. Variant rs377211288
was genotyped by KASPTM technology because it is not
covered by the Exome Chip. From the 23 genotyped variants,
only 14 variants were detected. The 2 variants rs61742518
(p.T433M) and rs146027075 (p.I479M) occurred with minor
allele frequencies of 2.68 and 0.96%, respectively, and were
therefore the only low-frequency variants. The remaining 12
variants occurred only heterozygously and were rare variants
with minor allele frequencies between 0.1 and 0.01% (5 variants)
or occurring in single individuals (7 “singleton” variants). The
genotype distributions of all variants fitted to the Hardy–
Weinberg equilibrium and are given in Table 3. Compared to
a large exome–genome–NGS cohort of non-Finnish Europeans
(gnomAD including 56,000 samples) (11), all variants were
covered with comparable minor allele frequencies (Table 2).
Associations of SLC22A9 Genetic Variants
With Bone Quality, Fracture Risk, and
Serum Bone Turnover Markers
Comprehensive single-variant association analyses were
performed for all 14 SLC22A9 genetic variants considering
an additive genetic model. For variants rs61742518 and
rs146027075, a dominant and recessive genetic model was
additionally considered because individuals with the respective
homozygous variant alleles were identified. After correction
for multiple testing, there were no significant associations
between QUS-based stiffness index, fractures, and serum
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TABLE 3 | Genotype distributions for the 14 SLC22A9 genetic variants identified in the SHIP and SHIP-TREND study cohort.
refSNP_ID db SNP
alleles
Genotype Number of
individualsa
Observed
heterozygote
frequency
Expected
heterozygote
frequency
HWE exact
p-value
rs377211288 (NA) C/T CC 5, 543 0.0009012 0.0009008 1
CT 5
TT 0
rs138297035 (exm920554) G/A GG 5, 700 0.0001754 0.0001754 1
GA 1
AA 0
rs202164269 (exm920556) C/G CC 5, 691 0.001754 0.001753 1
CG 10
GG 0
rs139591412 (exm920572) C/T CC 5, 639 0.000173 0.0001773 1
CT 1
TT 0
rs3737458 (exm920575) G/A GG 5, 700 0.0001754 0.0001754 1
GA 1
AA 0
rs200498139 (exm920580) C/A CC 5, 700 0.0001754 0.0001754 1
CA 1
AA 0
rs141060614 (exm920591) C/T CC 5, 700 0.0001754 0.0001754 1
CT 1
TT 0
rs182247457 (exm920593) A/G AA 5, 693 0.001403 0.001402 1
AG 8
GG 0
rs61742518 (exm920601) C/T CC 5, 397 0.05297 0.05223 0.4424
CT 302
TT 2
rs144303933 (exm920603) G/A GG 5, 700 0.0001754 0.0001754 1
GA 1
AA 0
rs139254772 (exm920609) T/A TT 5, 698 0.0005262 0.0005261 1
TA 3
AA 0
(Continued)
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TABLE 3 | Continued
refSNP_ID db SNP
alleles
Genotype Number of
individualsa
Observed
heterozygote
frequency
Expected
heterozygote
frequency
HWE exact
p-value
rs146027075 (exm920613) A/G AA 5, 593 0.01877 0.01894 0.4062
AG 107
GG 1
rs149660130 (exm920619) T/G TT 5, 699 0.0003508 0.0003508 1
TG 2
GG 0
rs142543443 (exm920628) C/T CC 5, 700 0.0001754 0.0001754 1
CT 1
TT 0
aNumbers are for bone quality.
HWE, Hardy–Weinberg equilibrium.
bone turnover markers and any of the low-frequency and
10 rare variants regardless of whether all individuals were
analyzed together or whether individuals were stratified
by sex (Supplementary Table 1). The singleton variants
rs200498139 and rs3737458 were significantly associated with
β-CTX and PINP, respectively, after correcting for multiple
testing (Supplementary Tables 1D,E). The two heterozygous
individuals carrying either variant had very low β-CTX or PINP
serum levels (Figure 1).
DISCUSSION
Estrogens play an important role in the resorption and formation
of bone and their age-dependent decrease is a major factor
for increased bone fragility and fragility-related fractures,
particularly in postmenopausal women (1). The metabolite
estrone sulfate is considered a major precursor of active estrogen
with serum levels about 10-fold higher than unconjugated
estrone (14). The absorption, disposition, and elimination of
estrone sulfate depend on multiple membrane transporters from
several families, including uptake transporters, e.g., the organic
anion transporters OAT3 (SLC22A8) andOAT4 (SLC22A11), the
organic anion transporting polypeptides OATP1B1 (SLCO1B1),
OATP1B3 (SLCO1B3), and OATP2B1 (SLCO2B1), as well as
ATP-dependent efflux transporters of the C subfamily (ABCC1,
ABCC2, ABCC3, and ABCC11) and ABCG2 (26–29). More
recent studies have identified OAT7 as an additional estrone
sulfate transporter (12, 13). A study examining Korean females
(8) even found the reduced-function variant p.F426S of OAT7
in women with osteoporosis but not in control subjects. This
study (8) failed, however, in providing exact methods regarding
osteoporosis diagnosis.
In the course of a systematic characterization, we had
identified and characterized three functionally relevant OAT7
variants in Europeans: p.R90C (rs377211288), p.T433M
(rs61742518), and p.I479M (rs146027075) (13). We therefore
tested the hypothesis whether these variants as well as additional
missense variants assessed by the Exome Chip also impact
on bone quality, assessed by heel QUS, in a population-based
European cohort. As there was no bone mineral density
measurement in our cohort, results are limited to provide
indices of the osteoporotic fracture risk instead of osteoporosis
itself. Neither the two low-frequency variants nor the five
rare nor most singleton variants were associated with the
QUS-based osteoporotic fracture risk, self-reported fractures,
or serum bone turnover markers. The observed significant
association of two singleton variants with β-CTX and PINP
is probably a spurious association and will need confirmation
in a much larger cohort. A major reason for this lack of
association may be the complex pathophysiology of bone loss,
which is not only caused by a number of genetic, biochemical,
hormonal, and environmental factors but apparently also
depends, among others, on ethnicity and lifestyle (1, 30).
Moreover, it appears that variants in a multitude of genes are
involved in maintenance of bone, each having only a small
effect size (1, 6, 7, 31). Morris et al., for example, identified
four low-frequency variants with small effect sizes on heel
BMD mapping to genes SLC22A24, SLC22A25, and SLC22A10,
being close to the SLC22A9 gene but not to the SLC22A9 gene
itself (7). However, these variants (rs117269586, rs138722111,
rs35740247, and rs56260618), which are available as imputed
variants in the SHIP and SHIP-TREND cohorts (32), were not
significantly associated with the bone stiffness index. Yet, a
role of this gene region in bone biology cannot be ruled out
and needs to be analyzed in studies using cohorts of diagnosed
osteoporosis patients, particularly because SLC22A24 had been
recently identified as an additional transporter of estrone sulfate
(33).
We studied a population-based cohort drawn from a general
population of Europeans that has been previously used to
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FIGURE 1 | Violin plots of β-CTX (A) and PINP (B) distribution in the study cohort stratified for sex. The blue dots indicate the heterozygous samples with significant
associations between rs200498139 and β-CTX (A) and rs3737458 and PINP (B). The blue lines indicate the median values; lower and upper black lines indicate the
1st and 3rd quartiles, respectively.
identify risk factors of osteoporosis (16). This population-based
study design and the number of participants are the main
strengths of the present study. While our study provides reliable
results on bone turnover and the osteoporotic fracture risk,
evidence on osteoporosis itself cannot be provided as dual-energy
X-ray absorptiometry (DXA) scans, using ionizing radiation,
were impossible in our population-based setting due to ethical
objections. However, despite the large number of participants,
this study has the limitation that it still may not be large enough
to estimate the effect of rare variants withminor allele frequencies
<0.01% and might be underpowered to identify significant
associations. This is particularly important for SLC22A9, for
which only rare variants exist in Europeans, except for one low-
frequency and one rare variant. Moreover, it cannot be excluded
that rare variants of SLC22A9, not captured by the Exome
Chip, with large effect sizes may exist, which needs investigation
in a much larger cohort. Novel technologies such as whole-
genome and whole-exome sequencing (31) may be instrumental
in identifying novel rare variants in SLC22A9 associated with
bone density.
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In conclusion, we found no association of SLC22A9 missense
variants with QUS-based bone quality, fractures, and serum bone
turnover markers. Our results indicate that, in contrast to the
situation in Koreans, single SLC22A9 genetic variants apparently
do not have a major impact on osteoporosis risk prediction
in Europeans.
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